A detailed history of First Trust Advisors LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, First Trust Advisors LP holds 140,924 shares of PTGX stock, worth $5.49 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
140,924
Previous 131,810 6.91%
Holding current value
$5.49 Million
Previous $4.57 Million 38.67%
% of portfolio
0.01%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$33.72 - $47.33 $307,324 - $431,365
9,114 Added 6.91%
140,924 $6.33 Million
Q2 2024

Aug 13, 2024

BUY
$24.66 - $34.8 $1.75 Million - $2.48 Million
71,147 Added 117.28%
131,810 $4.57 Million
Q1 2024

May 13, 2024

BUY
$21.79 - $32.15 $1.32 Million - $1.95 Million
60,663 New
60,663 $1.75 Million
Q2 2022

Aug 12, 2022

SELL
$7.06 - $25.52 $193,754 - $700,370
-27,444 Reduced 65.7%
14,328 $113,000
Q1 2022

May 13, 2022

BUY
$23.34 - $36.08 $974,958 - $1.51 Million
41,772 New
41,772 $989,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.91B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.